Results 91 to 100 of about 44,894 (310)
Genetics in Medicine, 2019 CYP2D6 bioactivates codeine and tramadol, with intermediate and poor metabolizers (IMs and PMs) expected to have impaired analgesia. This pragmatic proof-of-concept trial tested the effects of CYP2D6-guided opioid prescribing on pain control ...
D. M. Smith +19 more
semanticscholar +1 more source
Estrogen-Induced Cholestasis Leads to Repressed CYP2D6 Expression in CYP2D6-Humanized Mice [PDF]
Molecular Pharmacology, 2015 Cholestasis activates bile acid receptor farnesoid X receptor (FXR) and subsequently enhances hepatic expression of small heterodimer partner (SHP). We previously demonstrated that SHP represses the transactivation of cytochrome P450 2D6 (CYP2D6) promoter by hepatocyte nuclear factor (HNF) 4α.
Xian, Pan, Hyunyoung, Jeong
openaire +2 more sources
British Journal of Clinical Pharmacology, EarlyView.Aims Safe prescribing and effective medication review during acute hospitalization depends on accurate information about liver and kidney function because these organs are responsible for the elimination of most medications. While estimates for kidney function are widely used, comparable markers of hepatic drug‐metabolizing capacity are not routinely ...
Louise Westberg Strejby Christensen +17 more
wiley +1 more source
Substrate specificity of CYP2D6 genetic variants [PDF]
, 2021 Genetic variation in the gene encoding CYP2D6 is used to guide drug prescribing in clinical practice. However, genetic variants in CYP2D6 show substrate-specific effects that are currently not accounted for.
Guchelaar, H.J. +2 more
core +1 more source
Transgenic HepaRG cells expressing CYP2D6 as an improved model of primary human hepatocytes
Pharmacology Research & Perspectives, 2022 CYP2D6 and CYP3A4, which are members of the cytochrome P450 superfamily of metabolic enzymes, play major roles in the metabolism of commonly available drugs.
Shota Okuyama +5 more
doaj +1 more source
Frequencies of clinically important CYP2C19 and CYP2D6 alleles are graded across Europe
European Journal of Human Genetics, 2019 CYP2C19 and CYP2D6 are important drug-metabolizing enzymes that are involved in the metabolism of around 30% of all medications. Importantly, the corresponding genes are highly polymorphic and these genetic differences contribute to interindividual and ...
J. Petrović, V. Pešić, V. Lauschke
semanticscholar +1 more source
Clinical Pharmacology &Therapeutics, EarlyView.Risperidone is a commonly used antipsychotic for treating psychiatric illness in children and adolescents. There is a large variability in risperidone response and discontinuation rates remain high. Pharmacogenomics offers the opportunity to improve risperidone outcomes, yet studies in pediatric populations are limited.
Jack W. Staples +10 more
wiley +1 more source
CYP2D6 Substrate Dispensing Among Patients Dispensed Mirabegron: An Administrative Claims Analysis
Drugs - Real World Outcomes, 2022 Background Overactive bladder (OAB) is characterized by the presence of bothersome urinary symptoms. Pharmacologic treatment options for OAB include anticholinergics and β3-adrenergic agonists.
Mary E. Ritchey +7 more
doaj +1 more source
Clinical Pharmacology &Therapeutics, EarlyView.Lysosomes play a key role in the accumulation, catabolism, and transport of endogenous and exogenous metabolites and proteins and are involved in drug metabolism and prodrug activation. However, the protein abundance and interindividual variability of lysosomal drug‐metabolizing enzymes and transporters (DMETs) remain underexplored.
Darshak Gadara +20 more
wiley +1 more source
Clinical Pharmacology &Therapeutics, EarlyView.Rifampicin is a prototypical clinical inducer used in drug–drug interaction (DDI) studies. However, the clinical relevance and predictability of rifampicin‐mediated hepatic transporter induction remain poorly defined. Conventional hepatocyte culture models fail to capture clinically relevant regulation of transporters and drug‐metabolizing enzymes ...
Mattie E. Hartauer +9 more
wiley +1 more source